

5th Symposium on Cancer Immunology and Immunotherapy, December 5-7, 2019

Thursday, December 5th, 2019

15.00 - 15.15 Welcome

Session 1: Novel Immunotherapies for Cancer

Chairs: V.Georgoulas, A. Kotsakis

15.15 - 15.45 The cystine/glutamate antiporter xCT: one tumor antigen, multiple functions

F. Cavallo

15.45 – 16.15 CD4+ T cells as an emerging solution to treat solid tumors

EM. Inderberg

16.15 – 16.45 Genetically Modified T Cells for the Immunotherapy of Cancer

M.Nishimura

16.45 – 17.15 Coffee break

Session 2: Aging and cellular senescence in the era of cancer immunotherapy

Chairs: O. Tsitsilonis, I. Trougakos

17.15 – 17.45 Harnessing NK cells for cancer immunotherapy: impact of NK cell immunosenescence

R. Solana

17.45 – 18.15 Immunotherapy of cancer: triumphs and challenges, and the impact of immunosenescence in humans – is aging always a bad thing?

G. Pawelec

18.15 – 18.45 Interplay between cellular senescence and cancer

D. Kletsas


Plenary lecture

Chairs: C. Baxevanis, G. Pawelec

18.45 – 19.30 The role of microRNA in cancer

B. Seliger

20.00 Dinner



Friday, December 6th , 2019

Session 3: Tumor immune resistance and escape

Chairs: F. Cavallo, C. Baxevanis

9.30 – 10.00 Secondary immune resistance mechanisms induced by therapeutic cancer vaccines which prevent tumor regression and foster recurrences SH. van der Burg

10.00 – 10.30 Understanding how the immune system prevents tumor escape A. Madrigal

10.30 – 11.00 Roadblocks to cancer immunotherapy J. Wischhusen

11.00 – 11.30 Coffee break

Session 4: Tumor regression vs tumor progression: balancing T and NK cells vs Neutrophils and MDSC

Chairs: A. Madrigal, R. Solana

11.30 – 12.00 A complex interplay between dendritic cells, NK cells and T cells governs adaptive immune responses in tumor microenvironments. M. Tsooumakidou

12.00 – 12.30 Nuclear factor-kappa B-based tumor-host interactions in malignant pleural disease G. Stathopoulos

12.30 – 13.00 Neutrophils and MDSC as mediators of immune suppression and drivers of tumor progression S. Brandau

13.00 – 14.30 Lunch

14.30 – 16.30 **Short oral presentations (I)**

Chairs: V. Georgoulas, O. Tsitsilonis

16.30 – 17.00 Coffee break

Session 5: Immunomodulation and novel immune checkpoints

Chairs: G. Adema, B. Seliger

17:00-17:30 Opening a new therapeutic window for human bladder cancer D. Stravopodis

17.30 - 18.00 Immunomodulatory properties of chitinase-like proteins in tumor J. Kzhyshkowska


18.00 – 18.30 Discovery and validation of novel immune checkpoints for cancer immunotherapy in humanized mice G. Marodon

Plenary lectures

Chairs: D. Stravopodis, G. Kyrgias

18.30– 19.00 TBA G. Adema

19.00-19.30 Tumor Microenvironment and response to Radiotherapy and Immunotherapy M. Koukourakis



Saturday, December 7th, 2019

Session 6: The tumor microenvironment and immune regulation

Chairs: G. Koukoulis, A. Koutsopoulos

9.30 – 10.00	Immune cell infiltration in breast cancer	A. Giatromanolaki
10.00 – 10.30	Modulating the function of T regulatory cells	S. Lucas
10.30 – 11.00	Dynamic interactions within the tumor microenvironment	P. Foukas
11.00 -11.30	The targeting of the immune suppressive microenvironment with anti-regulatory T cells	E. Martinenaite

11.30 – 12.00 Coffee break

Session 7: Immunotherapies (I)

Chairs: A. Kotsakis, TBA

12.00 – 12.30	Cell-based Immunotherapy of solid tumors	J. Bartůňková
12.30 – 13.00	Treatment algorithm of NSCLC	E. Kontopodis
13.00 - 13.30	Update of the role of immunotherapy in melanoma	A. Laskarakis

14.00 – 15.00 Lunch

15.00-16.00 Short oral presentations (II)

Chairs: O. Tsitsilonis, G. Pawelec

Session 8: Immunotherapies (II)

Chairs: V. Georgoulis, A. Koumarianou

16.00-16.30	A novel biomarker and a new target for the immunotherapy of early stage ovarian cancer	B. Guinn
16.30-17.00	The emerging role of combinatorial regimens in renal cancer	K. Koutsoukos
17.00-17.30	Latest data for immunotherapy in urothelial cancer	F. Koinis
17.30 – 18.00	<u>Coffee break</u>	

Session 9: Immunotherapies (III)

Chairs: K. Baxevanis, J. Bartůňková

18.00-18.30	Rational bases of combining chemotherapy and immunotherapy and clinical applications	L. Crino
18.30-19.00	Adverse events from immunotherapy: Are they so rare?	A. Koumarianou
19.00-19.30	Hyperprogressive disease during immunotherapy	N. Pistalmatzian

19.30 **Awards – Closing Remarks (Georgoulis, Kotsakis, Tsitsilonis)**